Senate health committee Chair Bernie Sanders (I-VT) is calling on GlaxoSmithKline and Prasco Laboratories to cap the price of the authorized generic version of Flovent, a frequently prescribed inhaler for children, at $35. Sanders' appeal follows GSK's decision to stop selling Flovent last year and enter into an agreement with Prasco Laboratories to offer an authorized generic. The authorized generic version is currently priced between $172 and $313. FDA regards authorized generics as identical to their brand-name counterparts, and they...